

Title (en)  
METHODS AND COMPOSITIONS FOR REDUCING IMMUNOGENICITY BY NON-DEPLETIONAL B CELL INHIBITORS

Title (de)  
VERFAHREN UND ZUSAMMENSETZUNGEN ZUR VERMINDERUNG DER IMMUNOGENITÄT DURCH NICHT-DEPLETIONALE B-ZELL-INHIBITOREN

Title (fr)  
PROCÉDÉS ET COMPOSITIONS PERMETTANT DE RÉDUIRE L'IMMUNOGÉNÉCITÉ PAR DES INHIBITEURS DE LYMPHOCYTES B NON APPAUVRIS

Publication  
**EP 4004052 A4 20231101 (EN)**

Application  
**EP 20847569 A 20200730**

Priority

- US 201962880240 P 20190730
- US 2020044312 W 20200730

Abstract (en)  
[origin: CN114502587A] Disclosed herein in one aspect is a method of reducing immunogenicity comprising administering an effective amount of a non-depleting B-cell inhibitor to a patient who is receiving or has received a biotherapeutic agent. Related compositions are also provided. In some embodiments, the biotherapeutic agent is selected from one or more of gene therapy, gene editing therapy, messenger RNA (mRNA) therapy, oncolytic virus, enzyme replacement therapy, antibody therapy, protein therapy, and cell therapy.

IPC 8 full level  
**C07K 16/28** (2006.01); **C12N 5/00** (2006.01)

CPC (source: EP IL)  
**A61K 31/436** (2013.01 - EP IL); **A61K 38/1774** (2013.01 - EP IL); **A61K 38/4873** (2013.01 - EP IL); **A61K 39/39** (2013.01 - EP IL); **A61K 39/39541** (2013.01 - EP IL); **A61K 39/3955** (2013.01 - IL); **A61K 48/00** (2013.01 - IL); **A61K 48/0083** (2013.01 - EP IL); **A61P 37/02** (2017.12 - IL); **C07K 16/2803** (2013.01 - EP IL); **C07K 16/283** (2013.01 - EP IL); **C12Y 304/2201** (2013.01 - EP IL); **A61K 2039/505** (2013.01 - EP IL); **A61K 2039/525** (2013.01 - EP IL); **A61K 2039/545** (2013.01 - EP IL); **A61K 2039/577** (2013.01 - EP IL); **A61K 2300/00** (2013.01 - IL); **A61P 37/02** (2017.12 - EP); **C07K 2317/31** (2013.01 - EP IL); **C07K 2317/52** (2013.01 - IL); **C07K 2317/626** (2013.01 - EP IL); **C07K 2317/76** (2013.01 - EP IL); **C07K 2317/94** (2013.01 - EP IL); **C12N 2750/14143** (2013.01 - EP IL)

Citation (search report)

- [E] WO 2021022072 A1 20210204 - PROVENTION BIO INC [US]
- [XI] W CHEN: "Immunomodulatory effects of MGD010, a dart molecule targeting human B-CELL CD32B and CD79B", ANNALS OF THE RHEUMATIC DISEASES, vol. 76, no. Suppl. 2, 14 June 2017 (2017-06-14), pages SAT0027, XP055409158
- [XI] W CHEN ET AL: "SAT0027 Immunomodulatory effects of MGD010, a dart® molecule targeting human B-CELL CD32B and CD79B | Annals of the Rheumatic Diseases", 17 June 2017 (2017-06-17), XP055692403, Retrieved from the Internet <URL:https://ard.bmj.com/content/76/Suppl\_2/777.3> [retrieved on 20200506]
- See references of WO 2021022072A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
CN 114502587 A 20220513; EP 4004052 A1 20220601; EP 4004052 A4 20231101

DOCDB simple family (application)  
CN 202080064005 A 20200730; EP 20847569 A 20200730